PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8-K on May 4, 2026 (Item 2.02 and 8.01) announcing preliminary financial results for the quarter ended March 31, 2026 and updated timelines for its atrial fibrillation (AF) clinical programs. The company expects to report approximately $68.3 million in cash and cash equivalents and about $0.2 million in net accounts receivable as of March 31, 2026. For the quarter, Pulse expects net cash used in operating activities of roughly $14.6 million and a net loss of approximately $18.6 million. These figures are preliminary, unaudited and subject to completion of closing procedures.

Key Details

• Preliminary Q1 2026 results: net loss ≈ $18.6 million.
• Cash position (Mar 31, 2026): ≈ $68.3 million; net accounts receivable ≈ $0.2 million.
• Q1 operating items: product revenue ≈ $0.4M; cost of product revenue ≈ $0.4M; R&D ≈ $12.6M; SG&A ≈ $6.6M; net cash used in operations ≈ $14.6M.
• Clinical updates: NANOPULSE-AF (pivotal, ~215 participants) — primary endpoints at 6 and 12 months; NANOCLAMP-AF (single-arm surgical study) — expected to complete enrollment by end of H1 2027, with multiple sites including two outside the U.S.

Why It Matters
These preliminary quarterly results show continued cash runway (cash ≈ $68M) but a sizeable operating cash burn and loss driven by R&D and SG&A as Pulse advances its cardiac device programs. For investors, the clinical enrollment acceleration is a material operational update: completing enrollment faster in the NANOPULSE-AF and NANOCLAMP-AF trials moves the company toward key 6- and 12-month efficacy/safety readouts that could affect regulatory and commercialization prospects. Note the financial numbers are unaudited and may change when the company files its formal quarterly report.